Axogen, Inc. (AXGN) Stock Price, News, Quote & History
This article provides a comprehensive overview of Axogen, Inc. (AXGN), a medical device company specializing in peripheral nerve regeneration. It details the company's stock performance, key financial metrics, product offerings, and recent news. The article also includes analyst insights and a comparison of Axogen's returns against the S&P 500.
A passive stake above 5% in Axogen (AXGN) is held through advisory clients.
Divisadero Street Capital Management, LP and its affiliated entities have reported a passive stake in Axogen Inc. (AXGN) via a Schedule 13G filing. Divisadero Street Capital Management, LP, William Zolezzi, and Divisadero Street Capital, LLC each reported beneficial ownership of 3,983,783 shares, representing 6.8% of Axogen's common stock. Additionally, Divisadero Street Partners, L.P. and Divisadero Street Partners GP, LLC reported 3,436,008 shares, or 5.9%.
Foley Hoag Advises Axogen on $200M Acquisition of BioCircuit Technologies
Foley Hoag advised Axogen, Inc. on its $200 million acquisition of BioCircuit Technologies, Inc. This acquisition expands Axogen's portfolio by adding NerveTape™, an FDA-cleared device for sutureless peripheral nerve repair. The Foley Hoag team, led by Mark Haddad, facilitated the deal which aims to enhance peripheral nerve repair procedures.
Axogen Completes Acquisition of BioCircuit Technologies,
Axogen, Inc. has completed its acquisition of BioCircuit Technologies, gaining NerveTape™, the first FDA-cleared device for sutureless peripheral nerve repair. This acquisition is expected to contribute significantly to Axogen's revenue, with projections of approximately $6 million in Q4 2026 and $34 million in 2027, and aligns with Axogen's mission to enhance peripheral nerve function restoration. The company anticipates NerveTape will become a new standard of care due to its simpler, faster, and more effective repair method compared to microsuturing.
AxoGen | 144: Notice of proposed sale of securities pursuant to Rule 144
This article is a notice regarding the proposed sale of securities by AxoGen, issued pursuant to Rule 144. It indicates an intention to sell securities under specific conditions. Further details would typically be found within the linked document.
Axogen completes acquisition of BioCircuit Technologies
Axogen Inc. (NASDAQ:AXGN) has announced the completion of its acquisition of BioCircuit Technologies Inc., a privately held medical device company. This acquisition adds NerveTape, an FDA-cleared sutureless device for repairing transected nerves, to Axogen's product portfolio. Axogen anticipates this acquisition to contribute approximately $6 million to Q4 2026 revenue and $34 million to 2027 revenue, supplementing their previously issued guidance for 2026.
Form 8K Axogen Inc For: 1 October By Investing.com
This article reports on Axogen Inc.'s Form 8K filing for October 1st. It highlights the company's stock symbol AXGN, which saw a -4.77% change, and lists various financial market data including indices, commodities, and individual stock performances. The content also features popular news and market movers.
Axogen Completes Acquisition of BioCircuit Technologies, Adding NerveTape™, the First FDA Cleared Device for Sutureless Peripheral Nerve Repair
Axogen, a leader in peripheral nerve function restoration, announced the completion of its acquisition of BioCircuit Technologies. This acquisition adds NerveTape™, the first FDA-cleared sutureless device for nerve repair, to Axogen's product portfolio. Axogen anticipates this will significantly contribute to revenue in Q4 2026 and 2027, enhancing their mission to improve peripheral nerve repair as a standard of care.
Axogen Completes Acquisition of BioCircuit Technologies, Expanding Peripheral Nerve Repair Portfolio
Axogen, Inc. has finalized its acquisition of BioCircuit Technologies, integrating NerveTape™, the first FDA-cleared sutureless nerve repair device, into its portfolio. This acquisition is projected to add approximately $6 million in revenue for Q4 2026 and $34 million for 2027, surpassing previous growth guidance. The move aims to enhance surgical solutions for peripheral nerve function restoration and maintain Axogen's financial health, with a projected gross margin of at least 73% and free cash positive status for 2026.
Truist cuts AxoGen stock price target to $53 on dilution concerns
Truist Securities has lowered its price target for AxoGen, Inc. (NASDAQ:AXGN) to $53 from $60, while maintaining a Buy rating, due to concerns over equity dilution from the BioCircuit acquisition. Despite the reduction, the new target still indicates a potential 26% upside. The firm anticipates strong revenue growth for AxoGen, exceeding 20% annually from 2026 through 2029, driven by the Breast segment and an expanded sales force, and positive feedback was received regarding the acquired Nerve Tape technology.
Truist reiterates Buy on AxoGen stock after Aetna coverage win
Truist Securities has reiterated a Buy rating and a $60.00 price target for AxoGen, Inc. after Aetna expanded its coverage policy to include AxoGen's Avance nerve allograft. This policy update increases the covered lives for Avance to the mid-90% range and reflects strong revenue growth and gross profit margins for AxoGen. Despite a significant stock surge, some analysis suggests the shares may be overvalued relative to their Fair Value.
Truist reiterates Buy on AxoGen stock after Aetna coverage win
Truist Securities has reiterated its Buy rating and $60.00 price target for AxoGen, Inc. (NASDAQ:AXGN) following Aetna's expanded insurance coverage for AxoGen’s Avance nerve allograft. This update considers Avance medically necessary for short-to-medium sensory nerve gaps in the upper extremity, increasing covered lives to the mid-90% range. The company has demonstrated strong financial performance with 24% revenue growth and a 75% gross profit margin, although InvestingPro suggests shares might be overvalued.
What Is Drawing Attention To Axogen (AXGN)?
Axogen (AXGN) has garnered attention due to recent share price movements, showing a decline over the past month and three months but significant gains over the last year. Despite the recent pullback, which has brought its price to approximately 11% below an estimated intrinsic value and 25% below the average analyst target, the company's valuation narrative suggests it is 19% undervalued at $53.22. However, the article also notes potential risks due to Axogen's reliance on its Avance Nerve Graft and a high P/S ratio compared to industry peers.
Raymond James raises AxoGen stock price target on growth outlook By Investing.com
Raymond James has increased its price target for AxoGen (NASDAQ:AXGN) to $53.00 from $48.00, maintaining an Outperform rating due to the company's attractive growth profile in the medical technology sector. Analysts anticipate AxoGen will achieve profitability this year, driven by strong revenue growth, particularly in its Breast segment, and strategic initiatives. This positive outlook follows recent robust financial results and similar price target increases from other firms.
AxoGen (AXGN) Short Interest & Short Float | Updated Sep 2026
As of September 15, 2026, AxoGen (AXGN) had a short interest of 4.06 million shares, an increase of 6.46% from the previous report. This represents 7.73% of the public float, with a short interest ratio of 2.9 days to cover. The article provides a detailed historical overview of AxoGen's short interest data, metrics, and comparisons to other companies in the healthcare equipment industry.
Axogen Inc (AXGN) Shares Fall 3.0% -- GF Value Says Still Overva
Axogen Inc (AXGN) shares dropped 3.0%, closing at $44.54, and are currently 155.7% overvalued according to GuruFocus' GF Value™ of $17.42. Despite an above-average GF Score™ of 64/100, indicating good business quality, the company faces challenges with unprofitability and a cash-flow-negative status, along with significant insider selling totaling $19.9 million over the past year. This combination suggests caution for potential investors due to the high valuation and lack of insider confidence.
Axogen, Inc. - Common Stock (Nasdaq:AXGN) Stock Quote
This article provides a stock quote for Axogen, Inc. (Nasdaq: AXGN), detailing its current trading price, daily range, 52-week range, and recent performance metrics. It also includes a list of recent news headlines related to the company, such as public offerings, acquisitions, earnings reports, and conference participations, along with frequently asked questions about its public trading status and market capitalization.
AxoGen, Inc. (AXGN) Stock Analysis: Healthcare Innovator With A 19% Potential Upside
AxoGen, Inc. (NASDAQ: AXGN), a medical devices company focused on peripheral nerve regeneration, shows a promising 19.02% potential upside despite not yet being profitable. The company, with a market capitalization of $2.66 billion, exhibits robust revenue growth of 23.10% and strong analyst confidence, with all 10 ratings being "buy." AxoGen's innovative product portfolio and strategic market expansion position it as a compelling opportunity for investors in the high-growth healthcare sector.
Axogen Prices $208.7 Million Public Offering
Axogen (AXGN) announced that it has priced an underwritten public offering of approximately 4.9 million shares. The offering is valued at $208.7 million. Further details are available to premium subscribers of MT Newswires.
Axogen Announces Pricing of $208.7 Million Public Offering of Common Stock
Axogen, Inc. announced the pricing of an underwritten public offering of 4,910,000 shares of its common stock at $42.50 per share, aiming to raise approximately $208.7 million. The proceeds are primarily intended to fund the cash consideration for its previously announced acquisition of BioCircuit Technologies, Inc., with any remaining funds for general corporate purposes. The offering is expected to close on September 11, 2026, and is not conditional on the acquisition.
Axogen deepens nerve repair portfolio through $200m BioCircuit takeover
Axogen is acquiring BioCircuit Technologies for $200 million in an all-cash deal expected to close in Q4 2026, significantly expanding its peripheral nerve repair portfolio. This acquisition adds NerveTape, the first FDA-cleared sutureless peripheral nerve repair technology, to Axogen's product line, aiming to simplify nerve repair for surgeons and accelerate market penetration. The move comes as competition in the nerve repair market intensifies, with other companies developing alternative sutureless technologies.
Axogen Announces Pricing of $208.7 Million Public Offering of Common Stock
Axogen, Inc. has announced the pricing of a public offering of 4,910,000 shares of its common stock at $42.50 per share, aiming to raise approximately $208.7 million. The company intends to use the net proceeds primarily to fund its acquisition of BioCircuit Technologies, Inc. and for general corporate purposes. The offering is expected to close on September 11, 2026, and is managed by lead book-running managers BofA Securities, Inc., Jefferies, and Wells Fargo Securities, LLC.
Axogen to buy BioCircuit Technologies for $200M
Axogen announced its agreement to acquire BioCircuit Technologies for $200 million, aiming to enhance its peripheral nerve repair offerings with BioCircuit's sutureless NerveTape device. The acquisition will be funded through a public equity offering. While analysts view the deal as a good strategic fit due to growth potential and margin accretion, the stock offering may cause investor contention.
Axogen stock falls as $208.7M offering dilutes shareholders
Axogen Inc (NASDAQ:AXGN) shares dropped 5.2% after pricing an underwritten public offering of 4.91 million shares at $42.50 each, which is expected to generate $208.7 million in gross proceeds. The offering will dilute existing shareholders and the proceeds will primarily fund the acquisition of BioCircuit Technologies, Inc. BofA Securities, Inc., Jefferies, and Wells Fargo Securities, LLC are lead managers for the offering.
Axogen, Inc. agreed to acquire BioCircuit Technologies, Inc. for approximately $200 million.
Axogen, Inc. has agreed to acquire BioCircuit Technologies, Inc. for approximately $200 million in cash. This acquisition will provide Axogen with BioCircuit's NerveTape and ConformaWrap products, enhancing its offerings for peripheral nerve repair. Axogen plans to finance the deal through a public offering of its common stock and expects the transaction, valued at 8.3x BioCircuit's Q2 2026 annualized run-rate revenue, to be accretive to its revenue growth and adjusted EBITDA margins in the first year post-closing.
Axogen Raises $200 Million to Fund BioCircuit Buyout Focused on Sutureless Nerve Repair
Axogen Inc. announced its acquisition of BioCircuit Technologies Inc. for $200 million in cash, aiming to integrate BioCircuit's sutureless nerve repair device, NerveTape, into its product line. To fund the acquisition, Axogen launched a public offering of common stock expected to generate over $208 million. The company anticipates the buyout will enhance revenue growth, adjusted EPS, and EBITDA margins, with the transaction set to finalize in Q4 2026.
Axogen prices $208.7 million stock offering at $42.50 per share
Axogen Inc. has priced an underwritten public offering of 4,910,000 shares of common stock at $42.50 per share, aiming to raise approximately $208.7 million. The proceeds are primarily intended to fund the acquisition of BioCircuit Technologies Inc., with any remainder used for general corporate purposes. The offering is expected to close on Friday.
Axogen Enters into Definitive Agreement to Acquire BioCircuit Technologies
Axogen, a leader in peripheral nerve function solutions, announced its definitive agreement to acquire BioCircuit Technologies for $200 million in cash. This acquisition introduces NerveTape™, the first FDA-approved device for sutureless peripheral nerve repair, which is expected to expand Axogen's market, accelerate adoption through its existing infrastructure, and be accretive to revenue growth, adjusted EBITDA margin, and adjusted EPS within the first year. The transaction, approved by both boards, is anticipated to close in Q4 2026 and will be funded through a public offering of Axogen's common stock.
Axogen Enters into Definitive Agreement to Acquire BioCircuit Technologies
Axogen, Inc. announced a definitive agreement to acquire BioCircuit Technologies, Inc. for $200 million in cash. The acquisition includes NerveTape™, the first FDA-approved device for sutureless peripheral nerve repair, which is expected to expand Axogen's market and accelerate adoption within its focus areas. The transaction is anticipated to be accretive to Axogen's revenue growth, adjusted EBITDA margin, and adjusted EPS in the first year after closing, while maintaining positive free cash flow.
Axogen Director Tyndall Joseph A. Disposes of 3,500 Shares at $49.70 Each
Axogen director Tyndall Joseph A. sold 3,500 shares of the company's stock at $49.70 per share on September 2, 2026. After this transaction, he holds 10,650 shares. This sale updates his ownership stake in Axogen.
Axogen, Inc. to Participate in the 24th Annual Morgan Stanley Global Healthcare Conference
Axogen, Inc. (NASDAQ: AXGN) announced its participation in the 24th Annual Morgan Stanley Global Healthcare Conference. Management will be available for one-on-one investor meetings on Tuesday, September 15, 2026. Axogen specializes in developing and marketing surgical solutions for peripheral nerve function restoration.
Axogen, Inc. to Participate in the 24th Annual Morgan Stanley Global Healthcare Conference
Axogen, Inc. (NASDAQ: AXGN) announced its participation in the 24th Annual Morgan Stanley Global Healthcare Conference on Tuesday, September 15, 2026. Management will be available for one-on-one investor meetings at the event. Axogen specializes in developing and marketing surgical solutions for peripheral nerve function restoration, offering a portfolio of products for nerve regeneration and repair.
Axogen, Inc. to Participate in the 24th Annual Morgan Stanley Global Healthcare Conference
Axogen, Inc. (NASDAQ: AXGN), a leader in peripheral nerve function restoration, announced its management will attend the 24th Annual Morgan Stanley Global Healthcare Conference on September 15, 2026, for one-on-one investor meetings. The company specializes in technologies for peripheral nerve regeneration and repair, offering solutions like Avance® Nerve Graft and Axoguard Nerve Protector®. This participation highlights their commitment to engaging with investors and showcasing their innovative surgical solutions.
Axogen stock hits 52-week high at 51.13 USD
Axogen Inc.'s stock reached a new 52-week high of $51.13, reflecting a remarkable 214.19% increase over the past year. Despite this growth and positive revenue figures, an InvestingPro tip suggests the stock might be overvalued. Analysts have raised price targets, highlighting the company's strong market position and growth prospects in the peripheral nerve repair market.
Truist initiates AxoGen stock with buy rating on growth potential
Truist Securities has initiated coverage on AxoGen, Inc. (NASDAQ:AXGN) with a buy rating and a $60.00 price target, citing the company's strong position in the peripheral nerve repair market and its potential for sustained double-digit growth. The firm projects revenue growth above 20% through 2029, with AxoGen outperforming the IHI index over the last twelve months. This positive outlook follows AxoGen's strong Q2 2026 financial results, which showed significant revenue growth and met adjusted EPS expectations.
Axogen (AXGN) Is Up 5.1% After Raising 2026 Outlook On Breast Reconstruction Surge - Has The Bull Case Changed?
Axogen (AXGN) saw its stock rise by 5.1% after reporting strong Q2 2026 sales of US$69.73 million and raising its full-year revenue outlook to at least US$279 million, driven significantly by its breast reconstruction franchise. While this momentum strengthens the near-term investment case, the company still faces challenges with margin pressure and operating costs that could delay sustainable profitability. Despite these risks, analyst forecasts suggest a potential 23% upside to its current price based on projected revenue growth and earnings by 2029.
AxoGen (AXGN) Tops Q2 Earnings and Revenue Estimates
AxoGen (AXGN) reported strong Q2 earnings, surpassing Zacks Consensus Estimates for both earnings per share and revenue. The company posted $0.12 EPS against an estimated $0.09 and revenues of $69.73 million, exceeding the $66.85 million estimate. While the stock currently holds a Zacks Rank #3 (Hold), investors are anticipating management's future commentary and upcoming earnings estimates.
AXGN Jumps As Axogen Wins Wave Of Price Target Hikes
Axogen Inc. (AXGN) stock jumped 8.53% after its Q2 2026 revenue exceeded expectations and management raised its full-year revenue outlook. Several firms, including Canaccord and Jefferies, subsequently increased their price targets on AXGN to the $53-$55 range, reiterating Buy or Outperform ratings. The company's strong performance was driven by breast procedure growth, high gross margins, and a solid balance sheet with positive free cash flow.
Axogen Stock Climbs As Analysts Hike Price Targets After Q2 Beat
Axogen Inc. (AXGN) stock climbed over 8.5% after beating Q2 2026 revenue expectations and raising its full-year guidance. Analysts from multiple firms have increased their price targets for AXGN to $53-$55, maintaining Buy or Outperform ratings. Despite strong top-line growth and gross margins, the company reported a small net loss due to high operating costs, but maintains a strong balance sheet with no debt.
Operating margin % of Axogen, Inc. – BMV:AXGN
The article focuses on the operating margin percentage of Axogen, Inc. (BMV:AXGN), a company listed on the Mexican Stock Exchange under the Health Technology sector. It appears to be a financial data page from TradingView, indicating that the market for this stock was closed with no trades. The core content highlights the company's operating margin, period value, and changes.
Price to sales ratio of Axogen, Inc. – BMV:AXGN
This page provides financial information for Axogen, Inc. (BMV:AXGN) on TradingView, specifically focusing on its Price to Sales ratio. It indicates that the market for AXGN is currently closed with no trades. The content also lists various features and services offered by TradingView.
31,800 Shares in AxoGen, Inc. $AXGN Bought by Edmond DE Rothschild Holding S.A.
Edmond DE Rothschild Holding S.A. has acquired a new stake of 31,800 shares in AxoGen, Inc. (NASDAQ:AXGN) during the second quarter, valued at approximately $1,469,000. Other institutional investors like BlackRock Inc. and Deutsche Bank AG also increased their holdings. This comes as AxoGen reported strong Q2 earnings, meeting consensus estimates, despite recent insider stock sales.
Axogen, Inc. Cash Flow – BIVA:AXGN
Axogen, Inc. (BIVA:AXGN) reported its Q2 2026 free cash flow at 110.76 million MXN, a significant improvement from -52.88 million MXN in 2025. The company's operating cash flow for 2025 was 14.64 million MXN. The article provides a high-level overview of the company's cash flow activities for recent years.
Total assets of Axogen, Inc. – BMV:AXGN
This page from TradingView provides financial information for Axogen, Inc. (BMV:AXGN), specifically focusing on its total assets. The article indicates that the market was closed and no trades were made at the time of publication, and it highlights the availability of historical data for the company's assets.
AXGN Stock Price and Chart — BIVA:AXGN
This page provides a comprehensive overview of Axogen, Inc. (AXGN) stock, traded on BIVA. It includes key financial stats such as market capitalization, revenue, and EPS, along with company information and employee data. The article also features analyst ratings, investment ideas, and details on ETFs holding Axogen stock, offering a complete picture for potential investors.
Tocqueville Asset Management L.P. Takes $8.03 Million Position in AxoGen, Inc. $AXGN
Tocqueville Asset Management L.P. has acquired a new position in AxoGen, Inc. (NASDAQ:AXGN), purchasing 173,900 shares valued at approximately $8.03 million. Despite institutional investors owning over 80% of the company and a "Moderate Buy" consensus rating from analysts, AxoGen remains unprofitable, with insiders selling significant amounts of stock. The company recently reported quarterly revenue of $69.73 million and adjusted earnings of $0.12 per share, matching earnings expectations while exceeding revenue estimates.
Axogen stock reaches 52-week high at 50.0 USD
Axogen Inc. (AXGN) has reached a new 52-week high of $50.00, reflecting a 222.92% growth over the past year and strong market sentiment. Despite this achievement, InvestingPro analysis suggests the stock is overvalued. The company recently reported significant revenue growth of 23% in Q2 2026, surpassing analyst estimates, leading to increased price targets from H.C. Wainwright and Citizens.
Rice Hall James & Associates LLC Invests $3.41 Million in AxoGen, Inc. $AXGN
Rice Hall James & Associates LLC acquired a new stake of 73,903 shares in AxoGen, Inc. ($AXGN) during the second quarter, valued at approximately $3.41 million. Institutional investors collectively own 80.29% of AxoGen, while insider activity shows recent sales totaling $4.48 million. Analysts maintain a "Moderate Buy" rating for AxoGen with an average target price of $51.00, following the company's Q2 earnings report which met EPS estimates and exceeded revenue expectations.
689,833 Shares in AxoGen, Inc. $AXGN Bought by TimesSquare Capital Management LLC
TimesSquare Capital Management LLC has acquired 689,833 shares of AxoGen, Inc. (NASDAQ:AXGN) worth approximately $31.9 million, representing a 1.28% stake in the medical equipment provider. This move contributes to the 80.29% institutional ownership of the company. Despite recent insider selling, analysts maintain a "Moderate Buy" rating for AxoGen, with a consensus price target of $51.
Axogen director Amy Wendell sells $646k in shares
Axogen director Amy Wendell sold approximately $646,592 worth of common stock on August 11, 2026, following the exercise of employee stock options. This sale, conducted via a Rule 10b5-1 trading plan, occurred as the stock traded near its 52-week high, despite an InvestingPro analysis suggesting it might be overvalued. The company recently reported strong Q2 2026 revenue growth, exceeding Wall Street estimates, and received raised price targets from analysts.
